Abstract: The present invention generally relates to antigen binding receptors capable of specific binding to mutated Fc domains with reduced Fc receptor binding and T cells expressing these antigen binding receptors. More precisely, the present invention relates to T cells, transfected/transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. Furthermore, the invention relates to a kit comprising the T cells of the invention and/or nucleic acid molecules, vectors expressing antigen binding receptors of the present invention and (a) tumor targeting antibody/antibodies comprising a mutated Fc domain.

Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.

Abstract: The present invention generally relates to antibodies that bind to HLA-A2/WTI, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Abstract: The present invention relates to combination therapies employing 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, in combination with HER-2 targeting agents, the use of these combination therapies for the treatment of cancer, and methods of using the combination therapies.

Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.

Abstract: The present invention relates to the combination therapy of a bispecific antibody which binds human TYRP1 and CD3 and a second TYRP1-specific antibody.

Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.

Abstract: The present invention generally relates to improved Protease-activatable antigen-binding molecules that comprise an anti-idiotype-binding moiety which reversibly masks a CD3 antigen binding moiety of the molecule. Furthermore, the invention relates to novel Protease-cleavable peptide linkers and their used in such Protease-activatable antigen-binding molecules. In addition, the present invention relates to polynucleotides encoding such Protease-activated T cell binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the Protease-activated T cell binding molecules of the invention, and to methods of using the same, e.g., in the treatment of disease.

Abstract: The present invention generally relates to chimeric receptors comprising an extracellular domain comprising a mutated Fc domain. The invention also relates to transduced immune cells expressing the chimeric receptors of the invention and/or nucleic acid molecules encoding the chimeric receptors of the present invention. Further provided are kits comprising such cells and/or nucleic acid molecules encoding the chimeric receptors, and antibodies capable of binding to the chimeric receptors.

Abstract: The present invention relates to an onium-functionalized siloxane having the general Formula (X) or (X-A) as defined herein; a method for preparing the onium-functionalized siloxane; and its use as an antimicrobial agent.

Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

Abstract: The invention relates to a method and a device for operating a device that is mountable on the rear side of a motor vehicle body, for coupling a trailer and/or a load carrier unit, comprising a holding arm, which during operation is firmly connected at a first end to the motor vehicle body and at a second end carries a coupling element for the trailer and/or the load carrier unit, wherein during operation forces acting on the coupling element and transmitted from the holding arm to the motor vehicle body are detected by an evaluation unit using deformation sensors, wherein the holding arm has at least two deformation regions of which the deformation behavior in the event of a force acting on the holding arm is detected in each case by at least one deformation sensor that is rigidly coupled to the respective deformation region of the holding arm and as a result detects its deformation behavior.

Abstract: An adapter for wireless data transmission, in particular according to the “Bluetooth Low Energy” standard, is proposed. The adapter has a cylindrical housing whose radius is at least twice its height. The adapter includes a wireless transceiver and a processor arranged in the cylindrical housing and connected to the wireless transceiver, and a data interface connected to the processor. The processor is arranged to drive the transceiver and the data interface and can therewith transmit data wirelessly. Because the adapter for wireless data transmission has a flat design, it can be retrofitted in valve positioners. This makes it possible to retrofit commonly used valve positioners that until now do not have an option for wireless transmission of their status data with this adapter. As a result, these commonly used valve positioners also achieve the capability of wireless transmission of their status data.

Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) at least one moiety capable of specific binding to a costimulatory TNF receptor family member, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Abstract: The invention relates to Her2 targeting 4-1BB agonists, in particular 4-1BBL trimer-containing antigen binding molecules comprising at least one antigen binding domain capable of specific binding to Her2 and their use in the treatment of cancer as well as their use in combination with T-cell activating anti-CD3 bispecific antibodies.

Abstract: The present invention relates to Her2-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.

Abstract: The invention relates to novel bispecific antibodies consisting of two fusion polypeptides comprising two antigen binding domains capable of specific binding to a first target and one antigen binding domain capable of specific binding to a second target, and to methods of producing these molecules and to methods of using the same.

Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract: The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.